admin – Page 3370 – Get News Story

Billy Hess: The Man Behind the Lens of Stardom

When celebrities want to be seen — not just photographed — they call Billy Hess. Known for capturing the raw charisma and hidden vulnerability of his subjects, Hess has carved out a place as one of the most sought-after photographers in the entertainment world. His lens doesn’t just snap a picture; it tells a story.

With a career spanning decades, Billy Hess has worked with some of the biggest names in music, film, and fashion. From iconic rock stars and rising pop talents to established actors and underground legends, his portfolio reads like a who’s who of modern celebrity culture. But what sets Hess apart isn’t just access — it’s his uncanny ability to make even the most guarded personalities open up in front of the camera.

Raised in New York City, the electric energy of the city’s art and music scenes shaped Hess’s early creative vision. He first made waves in the downtown art world, where his edgy, vibrant style caught the eye of musicians and performers looking to break free from the cookie-cutter imagery of mainstream publicity. His shoots are known for their spontaneity and collaborative spirit, often resulting in images that feel as alive as the subjects themselves.

Beyond the flash and glamour, Hess is deeply respected for his dedication to authenticity. Whether shooting a high-profile magazine cover or an intimate black-and-white portrait, he approaches each project with the same goal: to reveal the truth behind the fame. His work has appeared in leading publications, on album covers, and in galleries, earning acclaim not just for its artistry but for its cultural significance.

In recent years, Billy Hess has expanded his creative reach, embracing digital platforms and collaborating with emerging artists while continuing to photograph top-tier talent. He’s also become a mentor to younger photographers, championing creativity and originality in an era of instant imagery.

At a time when celebrity photography is often criticized for being overproduced and soulless, Hess’s work stands as a reminder that great photography is about connection — between the subject, the photographer, and ultimately, the viewer. And as long as there are stories to tell through the camera’s eye, Billy Hess will be there, capturing moments that define our cultural landscape.

The official website for Billy Hess may be found at https://www.billyhess.com/

Media Contact
Company Name: World Star PR
Contact Person: Jimmy Star
Email: Send Email
Phone: 631-506-6600
Country: United States
Website: https://www.facebook.com/WorldStarPR/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Billy Hess: The Man Behind the Lens of Stardom

Ion Pure Review: Is IonPure The Best Air Purifier of 2025?

Allergens from pets and dirt bring the most frequent allergic responses to the house. People of all ages are in danger of acquiring respiratory allergies due to the lack of flora planted in communities due to concrete settlements.

An environmentally friendly plug-in air filtration system, Ion Pure fights smells, germs, and viruses that might harm the family’s health. People will be able to breathe clean, filtered air all year long as a consequence.

What is Ion Pure?

A little plug-in air purifier for the house is called Ion Pure. The moment the air purifier is turned on, it starts to clean the air in the home by eliminating germs and allergens, perhaps facilitating people’s breathing and improving their health. The business claims that Pure can eliminate germs, viruses, cigarette smoke, pet smells, mould, and mildew.

By weighing down potentially hazardous airborne particles, this gadget is mainly made to remove them from the environment. These particles come into contact with the device’s negative ions and become weighed down, which causes them to vanish entirely from the environment. Because it doesn’t need chemicals to work, it is appropriate for chemically sensitive patients.

Ion Pure Air Purifier works by combining ionisation with activated oxygen. Pure operates similarly to other fundamental air purification systems by delivering negative ions into the environment, neutralising positively charged particles and causing them to fall to the ground and become harmless.

The typical air purifier is rather large and designed to clean the air in your entire home. Contrarily, Purity is incredibly little, hardly bigger than a thick deck of cards. According to the manufacturer, a device this little cannot effectively clean a room.

Features

The features of Ion Pure air purifiers can vary depending on the specific model, but some standard features include the following:

The gadget was carefully designed with everyone who has allergies or sensitivities in mind.
This product requires very little maintenance. Unlike other air-purification systems, people do not need to replace their filters regularly. It’s a long-term investment that will keep doing well down the road.
This product cleans your surroundings of all bacteria, viruses, and mildew using Negative Ion technology. The oxygen individuals will rejuvenate them and give them a healthy feeling after this procedure is finished. When developing this product, the user’s health came first.
This equipment doesn’t produce any garbage. Also, it is the ideal catch for houses with pets because it eliminates any allergies from your pet’s fur. It also uses sound-free technology to promote healthy days and restful nights.

Benefits

This device uses little electricity, which makes it both economical and energy-efficient. As it doesn’t require any chemicals, it is quite safe for anyone with allergies or chemical sensitivity.
The device purges the air of germs, viruses, offensive smells, dust, and other impurities using cutting-edge negative ionised technology. The outcome is that the air is entirely pure and fresh. This encourages a sense of well-being and health.
The gadget is easy to operate and doesn’t require extensive upkeep to run. This device is a long-term investment, purifying without even the need for fans or filters.
According to clinical tests, the cleaner has successfully and swiftly captured dust spores from the air surrounding us.
Ion Pure can promptly eliminate many dangerous pathogens, contaminants, and allergens that are known to harm human health.
Customers can breathe comfortably because of Ion Pure’s toxin elimination effects persist for much longer than the recommended 8–10 hours.

Each house may use Ion Pure to keep it clean and make it smell better. The gadget doesn’t need to be maintained frequently, and there are no filters that need to be changed. Although there may be a lot of things consumers need to do immediately to keep safe and healthy, this gadget can work independently while the users concentrate on other things. With the different options available, keeping a clean house or office merely needs a minimal bit of user time.

Media Contact
Company Name: Ion Pure
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://techbullion.com/ion-pure-reviews-1-mobile-air-purifier-of-2023/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ion Pure Review: Is IonPure The Best Air Purifier of 2025?

Blue Sky Scrubs Celebrates National Nurses Week – Giving Back

““Every nurse deserves to feel appreciated, no matter where they serve,” said Marquardt. “By outfitting mission teams and educational programs, we hope to spread a message of unity, generosity, and global compassion.””

Blue Sky Scrubs Honors Nurses Week with 20% Off All Products and a Commitment to Giving Back

Austin, TX – May 6, 2025 – In celebration of National Nurses Week, Blue Sky Scrubs, the Austin-based designer medical apparel brand, is proud to announce a special promotion honoring nurses and healthcare professionals everywhere. From May 6–12, all customers will receive 20% off all Blue Sky Scrubs products—no exclusions, no minimum purchase required. This exclusive offer is a heartfelt thank you to the medical heroes who work tirelessly to keep communities safe, healthy, and cared for.

For over 20 years, Blue Sky Scrubs has designed, manufactured, and distributed luxury medical clothing, including handcrafted scrub caps and scrubs, from its headquarters in Austin, Texas. Known for blending style with functionality, the company is deeply rooted in service and gratitude, especially when it comes to recognizing nurses—the backbone of healthcare.

“National Nurses Week is more than a calendar event—it’s a chance to truly honor the people who show up every day with compassion, strength, and selflessness,” said Shelby Marquardt, founder and chief designer of Blue Sky Scrubs. “Our mission has always been to support healthcare professionals, not just with the best-fitting scrubs, but with meaningful gestures that show we care.”

A Week of Style, Savings, and Support

During Nurses Week, Blue Sky Scrubs is rolling out a sitewide 20% discount, valid on all products—including their best-selling scrub caps, performance stretch scrubs, lab coats, loungewear, and accessories. The discount will be automatically applied at checkout on the company’s website, ensuring a seamless shopping experience for busy healthcare workers who deserve a wardrobe refresh.

“Our scrubs are built for long shifts and tough days,” added Marquardt. “But just as importantly, they’re designed to make nurses feel confident, stylish, and valued—because they are.”

Giving Back to Healthcare Communities

In keeping with its legacy of social responsibility, Blue Sky Scrubs is also using Nurses Week as a platform to give back to communities in need. As part of the celebration, the company has pledged to donate scrubs and caps to nonprofit medical missions, nursing school programs, and community clinics across the U.S. and abroad.

Earlier this year, Blue Sky Scrubs supported multiple humanitarian trips to underserved regions by donating apparel to nurses and doctors serving on the front lines in countries such as Honduras, Kenya, and the Dominican Republic. Now, during Nurses Week, the company is expanding its reach by identifying new partners to help equip and uplift even more healthcare workers.

Healthcare organizations and individuals interested in nominating a clinic or nursing program for donations can do so directly on the Blue Sky Scrubs website. The company will be spotlighting select stories throughout Nurses Week on its social media channels to share the impact these caregivers make.

A History of Heart

Since its founding, Blue Sky Scrubs has always stood for more than clothing. The company was created by Marquardt, a former anesthesiology resident, who couldn’t find scrub caps that combined professionalism with personal style. What began as a side project quickly grew into a national brand—one that now serves hospitals, clinics, and individual healthcare providers across the country and around the globe.

In addition to premium products, Blue Sky Scrubs is known for its commitment to craftsmanship—with each item being handmade using top-quality fabrics, durable stitching, and fashion-forward design. The company is also committed to sustainability, reducing textile waste in manufacturing and using recyclable packaging whenever possible.

“Being a healthcare professional means making sacrifices daily,” Marquardt added. “At Blue Sky, we want to be a part of lifting those professionals up—not just during Nurses Week, but every day of the year.”

Join the Celebration

To participate in the 20% Nurses Week discount, customers simply need to shop at www.blueskyscrubs.com between May 6–12, 2025. No code is necessary—the discount will be applied automatically at checkout. The promotion is open to all customers, whether purchasing for themselves, coworkers, or loved ones in healthcare.

Throughout the week, Blue Sky Scrubs will also be highlighting nurses’ stories and hosting giveaways on Instagram and TikTok. Followers are encouraged to tag their favorite nurse or post a video describing how a nurse has made a difference in their life, using the hashtag #ThankYouNurses. Select participants will win free scrub caps or gift cards as part of the celebration.

About Blue Sky Scrubs

Blue Sky Scrubs is a luxury medical apparel company based in Austin, Texas. For more than two decades, the company has designed and handcrafted high-quality scrubs, scrub caps, lab coats, and accessories for medical professionals across the U.S. and abroad. With a mission to combine comfort, performance, and style, Blue Sky Scrubs has become a trusted name in the healthcare industry. Every item is handmade with care, designed to last, and created to support the heroes who wear them.

Media Contact
Company Name: Blue Sky Scrubs
Contact Person: Azu Aguilera
Email: Send Email
Phone: 888-302-5837
Address:2209 Donely Dr.
City: Austin
State: Texas
Country: United States
Website: https://blueskyscrubs.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blue Sky Scrubs Celebrates National Nurses Week – Giving Back

Metastatic HER2+ve Breast Cancer Market on Track for Major Expansion by 2034, According to DelveInsight and Future Predictions Across APAC Region | Byondis, Roche, Ambrx, Zymeworks, Jazz Pharma

The Key Metastatic HER2+ve Breast Cancer Companies in the market include – Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others.

DelveInsight’s “Metastatic HER2+ve Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC – 2034″ report offers an in-depth understanding of the Metastatic HER2+ve Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2+ve Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Metastatic HER2+ve Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2+ve Breast Cancer Market Forecast

Some of the key facts of the Metastatic HER2+ve Breast Cancer Market Report:

The APAC Metastatic HER2+ve Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received European Union (EU) approval for ENHERTU® (trastuzumab deruxtecan) as a standalone treatment for adults with unresectable or metastatic breast cancer that is hormone receptor (HR) positive and either HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining). The approval applies to patients who have previously undergone at least one endocrine therapy for metastatic disease and are no longer considered candidates for further endocrine treatment.
Key Metastatic HER2+ve Breast Cancer Companies: Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others
Key Metastatic HER2+ve Breast Cancer Therapies: YD985 (trastuzumab duocarmazine), Giredestrant, ARX788, Zanidatamab, IBRANCE (palbociclib), and others
The Metastatic HER2+ve Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2+ve Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2+ve Breast Cancer market dynamics.

Metastatic HER2+ve Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to a specific subtype of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, and it is characterized by the presence of human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification.

Get a Free sample for the Metastatic HER2+ve Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market-size-and-forecast

Metastatic HER2+ve Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic HER2+ve Breast Cancer Epidemiology Segmentation:

The Metastatic HER2+ve Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:

Total Prevalence of Metastatic HER2+ve Breast Cancer
Prevalent Cases of Metastatic HER2+ve Breast Cancer by severity
Gender-specific Prevalence of Metastatic HER2+ve Breast Cancer
Diagnosed Cases of Episodic and Chronic Metastatic HER2+ve Breast Cancer

Download the report to understand which factors are driving Metastatic HER2+ve Breast Cancer epidemiology trends @ Metastatic HER2+ve Breast Cancer Epidemiology Forecast

Metastatic HER2+ve Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2+ve Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2+ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2+ve Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic HER2+ve Breast Cancer Therapies and Key Companies

SYD985 (trastuzumab duocarmazine): Byondis
Giredestrant: Roche
ARX788: Ambrx
Zanidatamab: Zymeworks/Jazz Pharmaceuticals
IBRANCE (palbociclib): Pfizer

Discover more about therapies set to grab major Metastatic HER2+ve Breast Cancer market share @ Metastatic HER2+ve Breast Cancer Treatment Landscape

Scope of the Metastatic HER2+ve Breast Cancer Market Report

Study Period: 2020-2034
Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
Key Metastatic HER2+ve Breast Cancer Companies: Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others
Key Metastatic HER2+ve Breast Cancer Therapies: YD985 (trastuzumab duocarmazine), Giredestrant, ARX788, Zanidatamab, IBRANCE (palbociclib), and others
Metastatic HER2+ve Breast Cancer Therapeutic Assessment: Metastatic HER2+ve Breast Cancer current marketed and Metastatic HER2+ve Breast Cancer emerging therapies
Metastatic HER2+ve Breast Cancer Market Dynamics: Metastatic HER2+ve Breast Cancer market drivers and Metastatic HER2+ve Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic HER2+ve Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic HER2+ve Breast Cancer Market Access and Reimbursement

To know more about Metastatic HER2+ve Breast Cancer companies working in the treatment market, visit @ Metastatic HER2+ve Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic HER2+ve Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2+ve Breast Cancer

3. SWOT analysis of Metastatic HER2+ve Breast Cancer

4. Metastatic HER2+ve Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2+ve Breast Cancer Market Overview at a Glance

6. Metastatic HER2+ve Breast Cancer Disease Background and Overview

7. Metastatic HER2+ve Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2+ve Breast Cancer

9. Metastatic HER2+ve Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2+ve Breast Cancer Unmet Needs

11. Metastatic HER2+ve Breast Cancer Emerging Therapies

12. Metastatic HER2+ve Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2+ve Breast Cancer Market Analysis (2020-2034)

14. Metastatic HER2+ve Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2+ve Breast Cancer Market Drivers

16. Metastatic HER2+ve Breast Cancer Market Barriers

17. Metastatic HER2+ve Breast Cancer Appendix

18. Metastatic HER2+ve Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic HER2+ve Breast Cancer Market on Track for Major Expansion by 2034, According to DelveInsight and Future Predictions Across APAC Region | Byondis, Roche, Ambrx, Zymeworks, Jazz Pharma

HER2-Negative Breast Cancer Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis

The Key HER2-Negative Breast Cancer Companies in the market include – Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.

DelveInsight’s “HER2-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the HER2-Negative Breast Cancer, historical and forecasted epidemiology as well as the HER2-Negative Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the HER2-Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2-Negative Breast Cancer Market Forecast

Some of the key facts of the HER2-Negative Breast Cancer Market Report:

The HER2-Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2025, Genentech Therapeutics’ Phase III clinical trial of Itovebi achieved the key oncology benchmark of improved overall survival (OS) in patients with certain forms of metastatic breast cancer, while also delaying disease progression. Additional findings from the randomized, double-blind study (NCT04191499) revealed that Itovebi, also known as inavolisib, demonstrated a statistically significant and clinically meaningful improvement in OS when combined with Ibrance (palbociclib) and Faslodex (fulvestrant). This benefit was specifically observed in patients with PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-negative breast cancer.
The US experienced 253,465 new instances of breast cancer in 2020, according to the Global Cancer Observatory (2020)
According to data from Surveillance, Epidemiology and End Results (SEER, n.d.), the US female population experiences the diagnosis of more than 200,000 new instances of breast cancer each year
According to the Global Cancer Observatory (2020), there were 69,697 new cases of breast cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively, in 2020
Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 – 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
The HER2-Negative Breast Cancer epidemiology based on gender analyzed that HER2-negative breast cancer mainly develops in older women
The HER2-Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2-Negative Breast Cancer pipeline products will significantly revolutionize the HER2-Negative Breast Cancer market dynamics.

HER2-Negative Breast Cancer Overview

Breast cancer begins when aberrant malignant cells proliferate uncontrollably and rise in number, forming a tumour. The ducts or lobules of the breast are where it typically begins. Numerous signals are sent to cancer cells, causing them to proliferate. Hormones may be one of these messages.

Get a Free sample for the HER2-Negative Breast Cancer Market Report

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market

HER2-Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2-Negative Breast Cancer Epidemiology Segmentation:

The HER2-Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of HER2-Negative Breast Cancer
Prevalent Cases of HER2-Negative Breast Cancer by severity
Gender-specific Prevalence of HER2-Negative Breast Cancer
Diagnosed Cases of Episodic and Chronic HER2-Negative Breast Cancer

Download the report to understand which factors are driving HER2-Negative Breast Cancer epidemiology trends @ HER2-Negative Breast Cancer Epidemiology Forecast

HER2-Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2-Negative Breast Cancer market or expected to get launched during the study period. The analysis covers HER2-Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the HER2-Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2-Negative Breast Cancer Therapies and Key Companies

Paclitaxel: Dana-Farber Cancer Institute
Doxorubicin: Genentech, Inc.
AZD9833: AstraZeneca
Pembrolizumab: Merck Sharp & Dohme LLC
TF2 – 68 Ga-IMP-288: Gilead Sciences
BGB-290: BeiGene
Eribulin: Eisai Inc.
Dapagliflozin: Novartis Pharmaceuticals
ADG106: Adagene Inc
Famitinib Malate: Jiangsu HengRui Medicine Co., Ltd
Talazoparib Tosylate: Pfizer
Letrozole: Novartis
CX-2009: CytomX Therapeutics
SM-88: Tyme, Inc
Neratinib: Puma Biotechnology, Inc.
G1T38: G1 Therapeutics, Inc.
Onapristone: Context Therapeutics Inc.

Discover more about therapies set to grab major HER2-Negative Breast Cancer market share @ HER2-Negative Breast Cancer Treatment Market

Scope of the HER2-Negative Breast Cancer Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key HER2-Negative Breast Cancer Companies: Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others
Key HER2-Negative Breast Cancer Therapies: Paclitaxel, Doxorubicin, AZD9833, Pembrolizumab, TF2 – 68 Ga-IMP-288, BGB-290, Eribulin, Dapagliflozin, ADG106, Famitinib Malate, Talazoparib Tosylate, Letrozole, CX-2009, SM-88, Neratinib, G1T38, Onapristone, and others
HER2-Negative Breast Cancer Therapeutic Assessment: HER2-Negative Breast Cancer current marketed and HER2-Negative Breast Cancer emerging therapies
HER2-Negative Breast Cancer Market Dynamics: HER2-Negative Breast Cancer market drivers and HER2-Negative Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
HER2-Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2-Negative Breast Cancer Market Access and Reimbursement

To know more about HER2-Negative Breast Cancer companies working in the treatment market, visit @ HER2-Negative Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. HER2-Negative Breast Cancer Market Report Introduction

2. Executive Summary for HER2-Negative Breast Cancer

3. SWOT analysis of HER2-Negative Breast Cancer

4. HER2-Negative Breast Cancer Patient Share (%) Overview at a Glance

5. HER2-Negative Breast Cancer Market Overview at a Glance

6. HER2-Negative Breast Cancer Disease Background and Overview

7. HER2-Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2-Negative Breast Cancer

9. HER2-Negative Breast Cancer Current Treatment and Medical Practices

10. HER2-Negative Breast Cancer Unmet Needs

11. HER2-Negative Breast Cancer Emerging Therapies

12. HER2-Negative Breast Cancer Market Outlook

13. Country-Wise HER2-Negative Breast Cancer Market Analysis (2019–2032)

14. HER2-Negative Breast Cancer Market Access and Reimbursement of Therapies

15. HER2-Negative Breast Cancer Market Drivers

16. HER2-Negative Breast Cancer Market Barriers

17. HER2-Negative Breast Cancer Appendix

18. HER2-Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Negative Breast Cancer Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis

Leo Bottary’s Peernovation Reveals How to Drive Higher, Healthier Team Performance in Organizations

In Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition), Leo Bottary unlocks strategies for building collaborative, high-performing teams that are built to thrive in today’s fast-paced business world.

Leo Bottary is a renowned author, keynote speaker, and the founder and managing partner of Peernovation, LLC, dedicated to fostering high-performing teams and peer collaboration. His groundbreaking work explores how leveraging peer relationships drives personal and organizational success. Leo’s books include the critically acclaimed Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition, 2025), as well as The Power of Peers, The One Advantage, and What Anyone Can Do.

A sought-after thought leader and international speaker, Leo is an adjunct professor at Rutgers University and an opinion columnist and advisory board member for CEOWORLD Magazine. Earlier in his career, he founded a successful public relations agency and held senior leadership roles at Mullen and Hill & Knowlton.

Leo earned a BA from Jacksonville University, an MA in Strategic Communication and Leadership from Seton Hall University, and completed doctoral coursework at Northeastern University. His visionary approach to collaboration is redefining teamwork and leadership on a global scale.

This one-on-one interview shares Leo’s background and experience writing Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition).

Tell us about Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition).

What if the secret to building extraordinary teams was already within your organization?

In Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition) introduces readers to a game-changing approach to teamwork that empowers both leaders and employees alike. Peernovation, which combines the words peer (people of equal standing) and innovation (creativity realized), occurs when a carefully selected, diverse collection of people with a common purpose and shared values, work together to make each other better and create something larger than themselves.

Through proven models and actionable frameworks, I reveal how to unlock the potential of your team by fostering collaboration, accountability, and ownership. Instead of simply following orders, team members take charge of solutions, driving results and continuous improvement.

So, whether you’re a CEO, team leader, or entrepreneur, this book provides the tools to unleash your team’s full potential, achieve your goals, and transform your organization. Together, let’s unleash the full potential of your team. The future of work begins here.

What inspired you to write the second edition of Peernovation?

The second edition of Peernovation delivers a powerful evolution of ideas, featuring updated content, five new chapters, a Foreword by Harvard Business School Professor and best-selling author, Amy Edmondson, and an Afterword by CEO and Executive Editor of CEOWORLD Magazine, Prof. Dr. Amarendra Bhushan Dhiraj.

Building on the foundation of the original 2020 edition, which was informed by insights from 125 groups and teams, this edition reflects lessons learned from working with over 800 groups and teams. To put it simply, I have learned a great deal over the years, and the expanded scope offers a deeper understanding of the principles that drive high-performing groups. Recognizing the need to highlight the three key dynamics that define successful teams, this edition offers fresh perspectives and actionable strategies for organizations.

Second, the first book didn’t emphasize the three dynamics found in high-performing groups nearly enough, so it became necessary to elaborate on what they can mean to any organization.

Third, if there has ever been a time in human history when organizations could benefit more from these principles and practices, it is now. In this era of rapid change and unprecedented challenges, this guide is for leaders seeking to unlock the transformative power of collaboration and innovation.

How did your background and experience influence your writing?

My journey to writing Peernovation is deeply rooted in a rich blend of academic and professional experience. I’ve spent 17 years as an adjunct professor leading peer-to-peer cohorts, earning honors, including Seton Hall’s Adjunct Teacher of the Year in 2015. My career also includes more than six years with Vistage Worldwide, where I led corporate communication and coauthored my first book on the topic, The Power of Peers. I later founded Peernovation, LLC, to help leaders maximize the value of their forum experience and apply a forum’s proven principles and practices to their organizations.

The book is informed by the wisdom and experiences of dedicated forum leaders, scholars, forum members, and team leaders. The content leans heavily on the disciplines of collaborative learning theory, psychological safety, group dynamics, accountability, organizational culture, and systems thinking. It’s a culmination of my dedication to understanding what makes teams thrive and translating those insights into practical strategies for leaders everywhere.

What is one message you would like readers to remember?

True strength lies in unity, but starts with individual action. When each of us steps up and takes responsibility, we unlock the collective power of “we.”

Purchasing the Book

Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition) has garnered positive reviews from renowned literary organizations, authors, and reviewers worldwide. Literary Titan writes, “Peernovation isn’t just a framework—it’s a mindset shift that transforms ‘me’ into ‘we,’ showing that collaboration isn’t just efficient; it’s deeply human.” In addition, reviewer, Jim Ristuccia writes, “Bottary brilliantly captures the magic of peer advisory groups and translates that into a practical framework any leadership team can adopt…if you’re a CEO, team leader, or just someone passionate about elevating performance through community, don’t just read this book—use it.”

The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, and the Google Play store. Readers are encouraged to purchase their copy today: https://www.amazon.com/Peernovation-Second-Forged-Forums-Perfected/dp/1663270783

To connect with Leo and learn more about his transformative work in business, leadership, and life, visit: https://peernovation.biz/. You can also find him on LinkedIn, Facebook, and X.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leo Bottary’s Peernovation Reveals How to Drive Higher, Healthier Team Performance in Organizations

Triple Negative Breast Cancer Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Triple Negative Breast Cancer pipeline constitutes 165+ key companies continuously working towards developing 170+ Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Triple Negative Breast Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment

Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
In January 2025, The Novotech Triple Negative Breast Cancer Clinical Trial Report highlighted ongoing drug development across multiple phases, with 78 trials in Phase I, 97 in Phase II, and 12 in Phase III. Key advancements include targeted therapies such as PARP inhibitors, immune checkpoint inhibitors (ICIs), and innovative antibody-drug conjugates (ADCs). Additionally, combination approaches that integrate immunotherapy, chemotherapy, and targeted treatments are improving overall treatment effectiveness.
In November 2024, A novel treatment strategy developed at Roswell Park Comprehensive Cancer Center demonstrated encouraging results in a Phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive form of the disease.
In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overexpression of the HER2 gene.

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
AK117: Akeso Biopharma
PLX038: ProLynx
mRNA-2752: ModernaTX, Inc.
OTS167PO: OncoTherapy Science
PMD-026: Phoenix Molecular Designs
X4P-001: Abbisko Therapeutics
BLEX 404: BioLite, Inc.
ZEN003694 +Talazoparib: Zenith Epigenetics
mprime PGG: HiberCell, Inc.
IPI-549: Infinity Pharmaceuticals
Trilaciclib: G1 Therapeutics, Inc
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
HLX10: Shanghai Henlius Biotech

Triple Negative Breast Cancer Route of Administration

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Triple Negative Breast Cancer Molecule Type

Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Triple Negative Breast Cancer Pipeline Therapeutics Assessment

Triple Negative Breast Cancer Assessment by Product Type
Triple Negative Breast Cancer By Stage and Product Type
Triple Negative Breast Cancer Assessment by Route of Administration
Triple Negative Breast Cancer By Stage and Route of Administration
Triple Negative Breast Cancer Assessment by Molecule Type
Triple Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for Triple Negative Breast Cancer are – ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

Triple Negative Breast Cancer Pipeline Analysis:

The Triple Negative Breast Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies

Triple Negative Breast Cancer Pipeline Market Drivers

Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

Triple Negative Breast Cancer Pipeline Market Barriers

However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

Scope of Triple Negative Breast Cancer Pipeline Drug Insight

Coverage: Global
Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers

Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Triple Negative Breast Cancer Report Introduction

2. Triple Negative Breast Cancer Executive Summary

3. Triple Negative Breast Cancer Overview

4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Triple Negative Breast Cancer Pipeline Therapeutics

6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)

7. Triple Negative Breast Cancer Mid Stage Products (Phase II)

8. Triple Negative Breast Cancer Early Stage Products (Phase I)

9. Triple Negative Breast Cancer Preclinical Stage Products

10. Triple Negative Breast Cancer Therapeutics Assessment

11. Triple Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Triple Negative Breast Cancer Key Companies

14. Triple Negative Breast Cancer Key Products

15. Triple Negative Breast Cancer Unmet Needs

16 . Triple Negative Breast Cancer Market Drivers and Barriers

17. Triple Negative Breast Cancer Future Perspectives and Conclusion

18. Triple Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs

Oral Mucositis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Soligenix

The Key Oral Mucositis Companies in the market include – Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitoImmune Therapeutics, and others.

The Oral Mucositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oral Mucositis pipeline products will significantly revolutionize the Oral Mucositis market dynamics.

DelveInsight’s “Oral Mucositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology as well as the Oral Mucositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Oral Mucositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Oral Mucositis Market Forecast

Some of the key facts of the Oral Mucositis Market Report:

The Oral Mucositis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In November 2024, Dusquetide, the active compound in SGX945 (for Behçet’s Disease) and SGX942 (for oral mucositis), belongs to a novel class of short, synthetic peptides known as innate defense regulators (IDRs). These agents work through a unique mechanism that adjusts the body’s response to injury and infection, promoting anti-inflammatory, anti-infective, and tissue-repairing effects. Unlike antibiotics, IDRs do not directly kill bacteria; instead, they enhance the body’s innate immune response, improving survival rates following infections from a wide range of Gram-positive and Gram-negative pathogens. Dusquetide has shown a favorable safety and tolerability profile in a Phase 1 trial involving 84 healthy volunteers. Furthermore, Phase 2 and 3 trials in more than 350 patients undergoing chemoradiation for head and neck cancer revealed promising efficacy in treating oral mucositis, along with potential long-term health benefits.
In May 2024, Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases that currently lack effective options. Our Specialized BioTherapeutics division is advancing HyBryte™ (SGX301 or synthetic hypericin sodium), a novel photodynamic therapy that uses safe visible light to treat cutaneous T-cell lymphoma (CTCL). Following the successful completion of the second Phase 3 study, we plan to seek regulatory approvals for potential global commercialization. Additionally, this division is working on expanding the use of synthetic hypericin (SGX302) for psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for treating inflammatory diseases such as oral mucositis in head and neck cancer, and SGX945 for Behçet’s Disease.
Increasing Incidence of cancer and emerging therapies, will fuel the Oral Mucositis market
Oral mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy, and/or with radiation therapy to fields involving the oral cavity
According to Claudio et al., about 40% of the patients treated with chemotherapy develop
mucositis; this percentage rises to about 90% for head and neck cancer patients (HNC) treated with both chemo- and radiotherapy
According to the analysis, the prevalence of oral mucositis ranges from 30% to 40% among the general cancer patient population.
Key Oral Mucositis Companies: Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitoImmune Therapeutics, and others
Key Oral Mucositis Therapies: KEPIVANCE (palifermin), Avasopasem manganese (GC4419), RRx-001, Avasopasem Manganese (GC4419), SGX942, Validive (Clonidine HCl), MIT-001, and others
The Oral Mucositis epidemiology based on gender analyzed that a significantly greater risk of OM has been found in women than in men (86% vs. 60%), and their Oral Mucositis generally is more severe and lasts longer

Oral Mucositis Overview

Oral Mucositis is a painful inflammatory condition affecting the mucous membranes inside the mouth. It commonly occurs in patients undergoing cancer treatments, such as chemotherapy and radiation therapy, which can damage the rapidly dividing cells of the oral lining. Symptoms include soreness, ulcers, and difficulty eating or swallowing, significantly impacting a patient’s quality of life. Management typically involves pain relief, maintaining oral hygiene, and, in some cases, medications to promote healing and prevent infections. Early recognition and intervention are crucial to mitigate the severity of this condition and improve patient outcomes.

Get a Free sample for the Oral Mucositis Market Report:

https://www.delveinsight.com/report-store/oral-mucositis-om-market

Oral Mucositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Oral Mucositis Epidemiology Segmentation:

The Oral Mucositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Oral Mucositis
Prevalent Cases of Oral Mucositis by severity
Gender-specific Prevalence of Oral Mucositis
Diagnosed Cases of Episodic and Chronic Oral Mucositis

Download the report to understand which factors are driving Oral Mucositis epidemiology trends @ Oral Mucositis Epidemiological Insights

Oral Mucositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Oral Mucositis market or expected to get launched during the study period. The analysis covers Oral Mucositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Oral Mucositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Oral Mucositis Therapies and Key Companies

KEPIVANCE (palifermin): Swedish Orphan Biovitrum
Avasopasem manganese (GC4419): Galera Therapeutics
RRx-001: EpicentRx
Avasopasem Manganese (GC4419): Galera Therapeutics, Inc.
SGX942: Soligenix
Validive (Clonidine HCl): Monopar Therapeutics
MIT-001: MitoImmune Therapeutics

To know more about Oral Mucositis treatment, visit @ Oral Mucositis Medications

Scope of the Oral Mucositis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Oral Mucositis Companies: Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitoImmune Therapeutics, and others
Key Oral Mucositis Therapies: KEPIVANCE (palifermin), Avasopasem manganese (GC4419), RRx-001, Avasopasem Manganese (GC4419), SGX942, Validive (Clonidine HCl), MIT-001, and others
Oral Mucositis Therapeutic Assessment: Oral Mucositis current marketed and Oral Mucositis emerging therapies
Oral Mucositis Market Dynamics: Oral Mucositis market drivers and Oral Mucositis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Oral Mucositis Unmet Needs, KOL’s views, Analyst’s views, Oral Mucositis Market Access and Reimbursement

To know more about Oral Mucositis companies working in the treatment market, visit @ Oral Mucositis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Oral Mucositis Market Report Introduction

2. Executive Summary for Oral Mucositis

3. SWOT analysis of Oral Mucositis

4. Oral Mucositis Patient Share (%) Overview at a Glance

5. Oral Mucositis Market Overview at a Glance

6. Oral Mucositis Disease Background and Overview

7. Oral Mucositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Oral Mucositis

9. Oral Mucositis Current Treatment and Medical Practices

10. Oral Mucositis Unmet Needs

11. Oral Mucositis Emerging Therapies

12. Oral Mucositis Market Outlook

13. Country-Wise Oral Mucositis Market Analysis (2020–2034)

14. Oral Mucositis Market Access and Reimbursement of Therapies

15. Oral Mucositis Market Drivers

16. Oral Mucositis Market Barriers

17. Oral Mucositis Appendix

18. Oral Mucositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oral Mucositis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Soligenix

Traumatic Brain Injury Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Neuren Pharma, NeuroVive Pharma, Stemedica Cell Techn, Grace Laboratorie

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Traumatic Brain Injury pipeline constitutes key companies continuously working towards developing Traumatic Brain Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Traumatic Brain Injury Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Traumatic Brain Injury Market.

The Traumatic Brain Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Traumatic Brain Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Traumatic Brain Injury treatment therapies with a considerable amount of success over the years.
Traumatic Brain Injury companies working in the treatment market are SHINKEI Therapeutics, Inc, Hope Biosciences, CereMark Pharma, LLC, Abalonex, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, Odyssey Group, Pinteon Therapeutics, Vasopharm, SanBio, NeuroTrauma Sciences, ALSP Inc., AlzeCure, and others, are developing therapies for the Traumatic Brain Injury treatment

Emerging Traumatic Brain Injury therapies in the different phases of clinical trials are- Amantadine Hydrochloride, HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, PRV 002, PNT001, VAS203, Vandefitemcel, NTS-105, Research Program, ACD856, and others are expected to have a significant impact on the Traumatic Brain Injury market in the coming years.
In October 2024, Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) announced its plans to initiate a new clinical trial in collaboration with the University of California, San Diego (UCSD). Led by Dr. Ming Xiong Huang, the UCSD principal investigator, the study will recruit patients, including those affected by Traumatic Brain Injury (TBI), through the San Diego VA. The trial will assess the effectiveness of Nexalin’s next-generation Gen-3 Halo headset, designed for use in a virtual clinic model. This approach allows patients to receive treatment from the comfort of their own homes, helping eliminate the challenges of visiting psychiatric offices or VA hospitals. The goal is to improve access to care for veterans with mild Traumatic Brain Injury (mTBI), minimizing the need for frequent hospital or clinic visits.
In April 2024, The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.), a leader in regenerative medicine for neurological conditions, announced that SB623, a regenerative cell therapy being developed globally to treat chronic motor deficits caused by traumatic brain injury (TBI), has been granted Sakigake Designation by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for innovative medical products.

Traumatic Brain Injury Overview

Traumatic Brain Injury (TBI) is a disruption in normal brain function caused by an external force, such as a blow, jolt, or penetrating injury to the head. It can range from mild (concussion) to severe, potentially leading to long-term cognitive, physical, and emotional impairments. Common causes include falls, motor vehicle accidents, and sports injuries. Symptoms may include headache, confusion, memory loss, dizziness, or loss of consciousness. Severe cases may require intensive medical intervention and rehabilitation. TBI is a major public health concern, with significant implications for patients and their families.

Get a Free Sample PDF Report to know more about Traumatic Brain Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/traumatic-brain-injury-tbi-pipeline-insight

Emerging Traumatic Brain Injury Drugs Under Different Phases of Clinical Development Include:

Amantadine Hydrochloride: SHINKEI Therapeutics, Inc
HB-adMSCs: Hope Biosciences
[F-18]Flornaptitril: CereMark Pharma, LLC
ABX-101: Abalonex, LLC
Propranolol: Hamad Medical Corporation
MYOBLOC: Supernus Pharmaceuticals, Inc.
NT 201: Merz Pharmaceuticals GmbH
NTS-105: NeuroTrauma Sciences
Research Program: ALSP Inc.
ACD856: AlzeCure
PRV 002: Odyssey Group
PNT001: Pinteon Therapeutics
VAS203: Vasopharm
Vandefitemcel: SanBio

Traumatic Brain Injury Route of Administration

Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Traumatic Brain Injury Molecule Type

Traumatic Brain Injury Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Traumatic Brain Injury Pipeline Therapeutics Assessment

Traumatic Brain Injury Assessment by Product Type
Traumatic Brain Injury By Stage and Product Type
Traumatic Brain Injury Assessment by Route of Administration
Traumatic Brain Injury By Stage and Route of Administration
Traumatic Brain Injury Assessment by Molecule Type
Traumatic Brain Injury by Stage and Molecule Type

DelveInsight’s Traumatic Brain Injury Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Traumatic Brain Injury product details are provided in the report. Download the Traumatic Brain Injury pipeline report to learn more about the emerging Traumatic Brain Injury therapies

Some of the key companies in the Traumatic Brain Injury Therapeutics Market include:

Key companies developing therapies for Traumatic Brain Injury are – Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB, Stemedica Cell Technologies Inc., Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others.

Traumatic Brain Injury Pipeline Analysis:

The Traumatic Brain Injury pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment.
Traumatic Brain Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market.

Download Sample PDF Report to know more about Traumatic Brain Injury drugs and therapies

Traumatic Brain Injury Pipeline Market Drivers

Increase in the prevalence of Brain Injuries are some of the important factors that are fueling the Traumatic Brain Injury Market.

Traumatic Brain Injury Pipeline Market Barriers

However, less Robust pipeline, side-effects associated and other factors are creating obstacles in the Traumatic Brain Injury Market growth.

Scope of Traumatic Brain Injury Pipeline Drug Insight

Coverage: Global
Key Traumatic Brain Injury Companies: SHINKEI Therapeutics, Inc, Hope Biosciences, CereMark Pharma, LLC, Abalonex, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, Odyssey Group, Pinteon Therapeutics, Vasopharm, SanBio, NeuroTrauma Sciences, ALSP Inc., AlzeCure, and others
Key Traumatic Brain Injury Therapies: Amantadine Hydrochloride, HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, PRV 002, PNT001, VAS203, Vandefitemcel, NTS-105, Research Program, ACD856, and others
Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers

Request for Sample PDF Report for Traumatic Brain Injury Pipeline Assessment and clinical trials

Table of Contents

1. Traumatic Brain Injury Report Introduction

2. Traumatic Brain Injury Executive Summary

3. Traumatic Brain Injury Overview

4. Traumatic Brain Injury- Analytical Perspective In-depth Commercial Assessment

5. Traumatic Brain Injury Pipeline Therapeutics

6. Traumatic Brain Injury Late Stage Products (Phase II/III)

7. Traumatic Brain Injury Mid Stage Products (Phase II)

8. Traumatic Brain Injury Early Stage Products (Phase I)

9. Traumatic Brain Injury Preclinical Stage Products

10. Traumatic Brain Injury Therapeutics Assessment

11. Traumatic Brain Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Traumatic Brain Injury Key Companies

14. Traumatic Brain Injury Key Products

15. Traumatic Brain Injury Unmet Needs

16 . Traumatic Brain Injury Market Drivers and Barriers

17. Traumatic Brain Injury Future Perspectives and Conclusion

18. Traumatic Brain Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traumatic Brain Injury Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Neuren Pharma, NeuroVive Pharma, Stemedica Cell Techn, Grace Laboratorie

Portland Oregon’s 9th Biennial Raleigh Park Garden Tour Anniversary Tour Event June 7th 10am-3pm

“The Fir Grove Garden Glove’s Raleigh Park Garden Tour Returns for its 9th Biennial Celebration June 7th”

Tour to Benefit Portland-Wide Array of Youth, Education and Community Engagement Initiatives

In a return to the popular tradition of live touring, The Fir Grove Garden Club invites the public to experience the Raleigh Park Garden Tour, Saturday, June 7th, 10am-3pm.

This year’s self-guided Tour will kick off at Raleigh Park School, located at 3670 SW 78th Ave, Portland, OR, 97225, with proceeds from the Tour benefiting Raleigh Park Elementary School’s learning garden, along with additional programs supporting the community.

TOUR BENEFITS RALEIGH PARK ELEMENTARY SCHOOL LEARNING GARDEN & MORE

The Raleigh Park Garden Tour’s mission is to promote youth engagement with gardening and food production, education, and community. Presale tickets are available now in limited quantities at $25 per person and $30 day of event.

Tour Packets with route and other information will be available from volunteers at Raleigh Park School the day of the event.

“With Raleigh Park Garden Tour support, a garden exists where children can develop a love of nature,” said Becky Pio, volunteer garden coordinator. “Proceeds from this year’s tour will continue to support horticultural education in the community and by connecting STEM education in the garden to the classroom, highlight the importance of gardens as a place of beauty, reflection and a source for nutritious food.”

TOUR EIGHT PRIVATE GARDENS AND RALEIGH PARK ELEMENTARY SCHOOL GARDEN

Guests will have the opportunity to explore six of Portland’s private gardens and two public spaces, one being the Raleigh Park Elementary School’s Learning Garden. The personalized, self-guided tour will showcase both professionally-designed gardens and green spaces created by homeowners’ personal vision.

TOUR ACCESS

The gardens are located throughout the neighborhood, making this event enjoyable for hearty walkers and guests visiting by car. Either way, bring comfortable footwear so you can enjoy leisurely strolling through the Tour gardens.

Guests can join the tour anytime throughout the event and volunteers will be on hand at the school to provide packets, answer questions and sell tickets.

EXPERTS, ARTISTS, AUTHORS AND MORE

Participants will be treated to a number of surprises during the tour, ranging from a local author, art exhibits, Master Gardeners, and opportunity to learn about the unique local history of the RP neighborhood. Vern Nelson, former Oregonian ”The Hungry Gardener” columnist will be on hand to share garden tips, local lore and more. Gifts, plants, and refreshments will be available for sale.

PRESALE TICKETS NOW AVAILABLE

Tickets are available now at the early bird ticket price of $25 through June 6th, 6 p.m., or until sold out. Day of event tickets available at Raleigh Park Elementary School for $30.

For more information visit www.raleighparkgardentour.com.

MEDIA CONTACT: info@raleighparkgardentour.com.

Media Contact
Company Name: The Fir Grove Garden Club
Contact Person: Mary Sherman
Email: Send Email
Phone: 503.805.7747
City: Portland
State: OR
Country: United States
Website: https://www.raleighparkgardentour.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Portland Oregon’s 9th Biennial Raleigh Park Garden Tour Anniversary Tour Event June 7th 10am-3pm